Diabetes mellitus consists of a chronic disease that currently stands out for its associated morbidity and mortality. The therapy is based on the association of different drugs and requires a change in the habits of the patients. The objective of the present study was to analyze the clinical and epidemiological profile of patients with type 2 diabetes mellitus assisted by the Specialized Component of Pharmaceutical Assistance of the state of Piauí. This was a descriptive, crosssectional study and analysis of social, demographic, economic, biochemical and anthropometric parameters. From the 93 participants, 66.7% were female, 57% had an average age of 60.5 years and 50.5% had a weight above 69 kg. The predominant family income was one minimum wage salary and the level of education reported was completed secondary education. It was found that 53.8% of the participants practiced regular physical activity and 87.1% had food restrictions. The most commonly used drug was vildagliptin. It was proven that 52.7% had unsatisfactory glycemic control considering the levels of HbA1c, as well as a necessity of a public state clinical protocol that regulates the dispensation of oral hypoglycemic agents in the state.
INTRODUCTION
Diabetes mellitus can be defined as a group of metabolic diseases characterized by increased blood glucose levels due to a disturbance in insulin secretion and/or action 1 . Among chronic noncommunicable diseases, diabetes stands out for its morbidity and mortality as a risk factor for cardiovascular diseases. In addition, high social and economic costs are involved in the treatment and result from the reduction of the quality of life of the individuals affected 2 . Type 2 diabetes mellitus (DM2) is the most prevalent form of the disease and basically results from varying degrees of insulin resistance and deficiency of hormone secretion. The risk of developing the disease increases with age and environmental factors such as sedentary lifestyle, obesity, alcoholism and smoking, in addition to a strong influence of the genetic component 1, 3 .
The current treatment aims to maintain adequate glycemic control by associating factors such as dietary reeducation, increased physical exercise practice and the use of appropriate medications 4 . However, because it is a progressive metabolic disorder, DM2 ends up being treated through the association of multiple drugs or with insulin administration for glycemic control, but management becomes even more complex due to the association of comorbidities 5 . Through an initiative of the Ministry of Health (MOH), programs have been created to address the diseases that have a major impact on the population. In this context, the Specialized Component of Pharmaceutical Assistance (CEAF) is responsible for dispensing drugs with high unit costs and those that become excessively expensive due to the total value of the treatment or the chronicity of the disease. Therefore, Pharmaceutical Assistance (PA) is inserted in this context by providing free and continuous supply of medicines for the treatment of various diseases, including DM2, as well as in monitoring the clinical conditions of each patient [6] [7] [8] . In Piauí, the State Department of Health (SESAPI) is responsible for supplying the specialized component drugs, including second-line oral hypoglycemic agents used in the refractory treatment of DM2, which are dispensed by the Pharmaceutical Assistance Unit Directorate (DUAF). Due to the lack of a Clinical Protocol and Therapeutic Guidelines (PCDT) for DM2, both at the state and federal levels, the DUAF follows the internal guidelines set forth in the medical literature to regulate the dispensing of drugs based on predefined criteria established, fundamentally, in the results of laboratory tests of fasting glycemia and glycated hemoglobin. The objective of the present study was to analyze the profile of people with DM2 assisted by the DUAF from an epidemiological and pharmacotherapeutic point of view.
METHODOLOGY

Study design and patient selection
This is a descriptive and cross-sectional study conducted at the DUAF located in the city of Teresina (PI). The unit is linked to the State Department of Health of Piauí (SESAPI) and responsible for dispensing CEAF medicines. Patients older than 18 years were included of both sexes with oral hypoglycemic therapy instituted and who were present at the DUAF dispensing pharmacy between August and September 2016 at the time of renewal of the treatment request, every 3 months, and or dispensing of the medication. Thus, those who underwent insulin therapy were excluded, since the research exclusively involved patients on oral hypoglycemic therapy. Those who were initiating treatment were excluded, that is, all patients who had not yet started therapy or who had less than 3 months of treatment, as well as patients who had discontinued treatment for any reason; since there would be previous or sufficient data from these patients for analysis.
Data collection
Data on the city of residence, sex, age, weight, height, body mass index (BMI) and results of the following glycemic control laboratory tests were collected from DUAF records: fasting glycemia, postprandial glycemia, and hemoglobin (HbA1c) collected in the physical processes of requesting dispensation of the hypoglycemic drugs provided by DUAF. All the data were tabulated in their own table elaborated in Microsoft Excel from the variables available above. Associated with this, data were collected from a form given to the participants in their own and individual room, regarding socioeconomic aspects, life habits and aspects related to the treatment of the patient. The application forms were then numerically identified, and the information collected was analyzed anonymously, assuring total confidentiality to the participants.
Ethical Considerations
The present study was approved by the Research Ethics Committee of the Federal University of Piauí (CEP-UFPI) under CAAE No. 54294616.3.0000.5214 and Opinion No. 1665.328, and it was initiated only after obtaining approval from CEP-UFPI. All participants were informed about the purpose and stages of the study, their risks and benefits with the signing of the Informed Consent Form (ICF) after their full understanding.
Statistical analysis
The variables were analyzed from the absolute frequency, simple percent, mean, and standard deviation by the IBM Statistical Package for Social Sciences (SPSS), version 23. The chi-square test was also used to apply the association hypothesis between the variables defined with confidence levels higher than 95% (p <0.05).
family income of a minimum wage salary was predominant with 31 (33.3%) patients.
According to Table 2 , the mean weight and height of the interviewees was 69.93±14.4 kg and 1.59±0.09 m respectively, resulting in a mean body mass index (BMI) of 27.58 kg/m 2 . Regarding lifestyle habits, 50 (53.8%) participants reported regular physical exercise, 81 (87.1%) reported that they did some type of diet, and among the foods most avoided, sugar stood out in 77 (82.8%) cases. However, only 27 (29.0%) reported avoiding regular consumption of soft drinks. It is noteworthy that 88 (94.6%) participants reported not having a smoking habit and 66 (71%) patients did not consume alcoholic beverages (Table 2) .
Statistical analysis and the evaluation of laboratory tests showed a higher frequency of female patients (79.1%) with DM2 who were simultaneously affected with dyslipidemia (Table 3) .
Considering the clinical history of the participants, 21 (70.0%) of the patients without systemic arterial hypertension (SAH) also did not present dyslipidemia, corroborating the relationship between these two clinical conditions (Table 4) .
Regarding the glycemic index, the results were mostly satisfactory, since 75.3%, 57.0% and 47.3% of the patients presented, respectively, values of postprandial glycemia, fasting glycemia and glycated hemoglobin (HbA1c) within ranges considered normal or tolerable for diabetics; that is, postprandial blood glucose lower than 180 mg/dL, fasting blood glucose lower than 130 mg/dL and HbA1c levels less than or equal to 7.0%2 ( Figure 1) .
As for pharmacotherapy, a higher frequency of dispensing of drugs containing the active agent vildagliptin was found. The pharmaceutical presentation with the drug isolated at a 50mg dose was used by 14.0% of the participants of the present study. The 5mg saxagliptin and 50mg sitagliptin were used alone by 5.4% and 3.2%, respectively. However, a greater number of dispensations involving pharmacological associations were demonstrated, since 53.8% of the patients used vildagliptin associated with metformin, which was the most widely used combination, followed by the presentation of sitagliptin associated with metformin that was used by only 7.6% of patients. For those in whom glycemic levels are extremely difficult to control, pioglitazone was added to therapy with these associated drugs, a fact found in a total of 14.0% of the patients involved in the present study (Figure 2 ). Profile of diabetic patients accompanied by the pharmaceutical assistance of Piauí, Brazil 
DISCUSSION
The epidemiological profile of the patients analyzed (Table 1 ) ratifies the study by , also carried out in the city of Teresina (PI), which described individuals with a mean age of 59.66±12.68 years, female, married, retired and having a monthly family income of 1 to 3 minimum wage salaries as a higher prevalence among patients enrolled in the Hyperdia program, which accompanies hypertensive and diabetic patients 8 . The number of people with diabetes mellitus has increased considerably in Brazil due to population growth and aging, greater urbanization and the progressive prevalence of both obesity and sedentary lifestyles 2 . In the present study, females presented a higher prevalence of DM2 (Table 1) , a fact that may be associated with women's greater concern about self-care and the demand for health services, although the disease is, according to the literature, more prevalent in men. For Galdas et al. (2015) , men as a group are often underrepresented in many health care programs and it is believed that in the question self-care, they are more negligent than women 9 . The participation of family members can be a beneficial factor in the management of the disease. It is important to pass on the basic information about DM2 treatment not only to the patient, but also to the members of their family group. Thus, it is possible to create an environment that reinforces adherence through simple attitudes such as remembering a medical appointment, medication administration times, preparing healthy meals and encouraging physical exercise, for example. Mayberry (2014), and report this information in their studies, with spouses and children cited as the main source of support. This information is more relevant considering that the majority of participants in this study are married patients (67.7%) [10] [11] [12] . Although it affects all social levels, schooling is directly related to self-care, that is, the lower the level of schooling the less self-care there is. Thus, the predominance of people with low levels of education portrays the greatest degree of difficulty in accessing information and health care 13 . However, among the participants, 21.5% had completed higher education (Table 1 ). In addition, we highlight the higher prevalence of diabetes among residents of urban centers. This is related to the stressful and agitated lifestyle of large cities or to the low coverage of the disease treatment in the interior of the states, a fact found in Piauí; a state in which the capital Teresina is a health reference throughout the northeastern region of Brazil 14 .
Family income is also something that directly interferes with self-care, since the low-income population has limited access to resources that can avoid risk factors and exposure to diabetes. Another important factor to consider is that the impact of social conditions on health occurs both through psychosocial and physiological pathways 15 . It is well known that in the clinical course of diabetes mellitus there is great concern about the possible incident comorbidities. The World Health Organization (WHO) classifies obesity based on the calculation of BMI and the risk of associated mortality. Thus, 45 (48.4%) of the patients were overweight, 19 (20.4%) presented grade I obesity and 4 (4.3%) grade II obesity. This finding indicates the need for guidelines on weight control, since obesity is one of the comorbidities considered as risk factors when associated with diabetes, as well as hypertension and dyslipidemias 16, 17 . Individuals who have concomitantly DM2 and SAH, for example, are at increased risk for developing kidney disease, coronary heart disease, stroke, and heart failure. When associated with dyslipidemia there is an increase in both morbidity and mortality in these patients 18 . Because of this, measures to prevent DM2 should be adopted to reduce or avoid such complications, such as health education actions and adoption of a healthy lifestyle, in order to obtain a satisfactory glycemic control 2 and avoid the culture of that only by using the drug will it be possible to achieve control of the disease. (Table 2) . Dyslipidemia, on the other hand, is a change in the metabolism of circulating lipoproteins in the blood that in DM2 patients is caused due to insulin resistance and obesity, and can be characterized by increased production of glucose, hypertriglyceridemia and VLDL, associating with the reduction in HDL and elevation in LDL. A higher prevalence of dyslipidemias in females was observed (Table 3) , a fact possibly associated with the onset of menopause; because along with the reduction of estrogen levels, there are naturally occurring changes in the lipid profile such as a drop in HDL cholesterol and progressive increase of LDL cholesterol, of total cholesterol and of triglycerides 19, 20 . In addition to what was described, hypertensive individuals frequently present high-level lipid profiles, as highlighted in Table 4 . The association of these conditions shows a strong influence of hypercholesterolemia, which in turn contributes to the progression of hypertension 21 . In relation to glycemic levels, the results were mostly satisfactory for fasting (57%) and postprandial (75.3%) glycemia levels as established by the Brazilian Society of Diabetes (2016). However, with regard to glycated hemoglobin (HbA1c) levels, it was observed that 52.7% (Figure 1 ) did not present ideal glycemic control, as opposed to the patients' reports regarding physical activity and food restriction listed in table 2. These results reflect that despite the effectiveness of the medication dispensed, there is the need for attention in the care of diabetic patients regarding the transfer of information regarding the pathophysiology of the disease and the need for constant performance of physical activities and diet, as previously mentioned.
Regarding the medications dispensed, the present research highlights the possibility of adjusting DUAF's drug list, which would result in a greater saving of public expenditures, since it would avoid the purchase of large quantities of drugs that are underutilized and which may consequentially expire, generating losses and health residues, as occurs for example with the combination of 50 mg sitagliptin and 500 mg metformin, dispensed to only 1.1% of the participants (Figure 2 ).
In addition, according to the literature, there are available effective and lower cost therapeutic alternatives to vildagliptin, given that this was the most recurrent active agent in the research (Figure 2) . , in a randomized study of 34 patients on metformin monotherapy and with uncontrolled glycemic levels, found that both vildagliptin and glimepiride when combined with metformin therapy similarly reduced blood glucose levels, which could represent a first line of therapeutic behavior to be adopted in the dispensation of oral hypoglycemic agents with Piauí pharmaceutical care. However, vildagliptin excels at glimepiride because it does not provide weight gain and promotes a lower incidence of hypoglycaemia 22 . Another recent study by conducted a cost-effectiveness analysis of metformin therapy combined with vildagliptin or glimepiride in 10,000 patients with DM2 with uncontrolled glycemic levels. It was observed that the addition of vildagliptin to therapy increased the costs of treatment more markedly compared to the addition of glimepiride. However, this increase was minimized by the reduction of costs of associated comorbidities and adverse events, as well as the increase in years of life as well as the quality of life of vildagliptin therapy patients. This confirms the importance of this active agent in the promotion, protection and recovery policies of the health of the diabetics but also emphasizes the need to adopt criteria in the acquisition, solicitation and dispensation of medicines based on vildagliptin 23 . It is suggested as a future criterion for the inclusion of a clinical state protocol for dispensing vildagliptin, the previous established treatment of glimepiride with metformin in patients with DM2, in order to rationalize the acquisition and use of the drug.
Thus, the performance of the pharmacist professional is indispensable for these patients providing pharmacotherapeutic monitoring and technical evaluation of the treatments requested, as well as in the specific action of managing the resources involved in the Pharmaceutical Assistance which contributes to a better quality of life of patients and better application of the resources of the Unified Health System (SUS).
CONCLUSION
Patients with DM2 assisted by DUAF are predominantly female obese individuals over 60 years of age living in the capital Teresina with full secondary education and monthly family income of one minimum wage salary. The study revealed that although a large proportion of the participants reported regular physical activity (53.8%) and dietary restrictions (87.1%), only 26.9% of the patients had a normal BMI. In addition, 52.7% had unsatisfactory glycemic control from the HbA1c values, the main laboratory marker of evaluation of the diabetic patient. The most commonly used drug was 50 mg vildagliptin, followed by its pharmacological presentation associated with metformin. The need for constant monitoring of the group of patients targeted by the present study was observed. In addition, associating new laboratory tests is recommended to evaluate the risks and benefits of oral hypoglycemic therapy, such as lipidogram, hepatic transaminases and renal function tests, especially if a significant majority of patients presents comorbidities. Evaluating the list of drugs standardized by the DUAF is also recommended, especially regarding active vildagliptin, in order to encourage the rational use of the drug and the optimization of public health resources. 
INTRODUÇÃO
O diabetes mellitus pode ser definido como um grupo de doenças metabólicas, caracterizado pelo aumento nos níveis de glicose sanguínea, devido a um distúrbio na secreção e/ou na ação da insulina 1 . Dentre as doenças crônicas não transmissíveis, o diabetes se destaca pela sua morbimortalidade e como fator de risco para doenças cardiovasculares. Além disso, altos custos sociais e econômicos são envolvidos no tratamento e decorrentes da redução da qualidade de vida dos indivíduos acometidos 2 . O diabetes mellitus do tipo 2 (DM2) é a forma mais prevalente da doença e resulta basicamente de graus variáveis de resistência à insulina e deficiência da secreção hormonal. O risco de desenvolvimento da doença aumenta com a idade e devido a fatores ambientais, como sedentarismo, obesidade, alcoolismo e tabagismo, além de ocorrer forte influência do componente genético 1, 3 . O tratamento atual visa manter o controle glicêmico adequado associando fatores como reeducação alimentar, aumento da prática de exercícios físicos e o uso de medicações apropriadas 4 . Contudo, por ser um distúrbio metabólico progressivo, o DM2 acaba sendo tratado através da associação de múltiplos fármacos ou com administração de insulina para o controle glicêmico, porém o manejo torna-se ainda mais complexo devido a associação de comorbidades 5 
Coleta de dados
Foram coletados junto aos registros da DUAF dados referentes ao município em que reside, sexo, idade, peso, altura, índice de massa corporal (IMC) e resultados dos seguintes exames laboratoriais de controle glicêmico: glicemia de jejum, glicemia pós-prandial e hemoglobina glicada (HbA1c) coletados nos processos físicos de solicitação de dispensação dos medicamentos hipoglicemiantes fornecidos pela DUAF. Todos os dados foram tabulados em tabela própria elaborada no Microsoft Excel a partir das variáveis disponíveis supracitadas. Associado a isso, foram coletados dados a partir de um formulário aplicado aos participantes em sala própria e individual, a respeito de aspectos socioeconômicos, hábitos de vida e aspectos relacionados ao tratamento do paciente. Os formulários aplicados receberam então uma identificação numérica e as informações reunidas foram analisadas anonimamente, assegurando total confidencialidade aos participantes. A análise estatística e a avaliação dos exames laboratoriais apresentados demonstraram maior frequência de pacientes do sexo feminino 34 (79,1%) com DM2 acometidos concomitantemente com dislipidemia (Tabela 3).
Considerações éticas
Considerando o histórico clínico dos participantes, dentre os pacientes que não apresentavam hipertensão arterial sistêmica (HAS), a maioria significativa, 21 (70,0%), também não apresentava dislipidemia corroborando a relação entre essas duas condições clínicas (Tabela 4).
Com relação ao índice glicêmico, os resultados encontrados foram satisfatórios para 75,3%, 57,0% e 47,3% dos pacientes, quanto aos valores de glicemia pós-prandial, glicemia de jejum e hemoglobina glicada (HbA1c), respectivamente. Estes pacientes apresentaram resultados de exames dentro dos intervalos considerados normais ou toleráveis para diabéticos, ou seja, glicemia pós-prandial menor que 180 mg/dL, glicemia de jejum inferior a 130 mg/dL e níveis de HbA1c menores ou iguais a 7,0% 2 (Figura 1).
Quanto à farmacoterapia, foi constatada maior frequência de dispensação de medicamentos contendo o princípio ativo vildagliptina. A apresentação farmacêutica com o fármaco isolado na dose de 50mg foi utilizado por 14,0% dos participantes do presente estudo. A saxagliptina 5 mg, a sitagliptina 50 mg e a pioglitazona 30 mg foram utilizadas isoladamente por 5,4%, 3,2% e 2,2% dos participantes, respectivamente.
Entretanto, foi evidenciada uma maior quantidade de dispensações envolvendo associações farmacológicas, pois 53,6% dos pacientes utilizavam vildagliptina associada à metformina, sendo esta, portanto, a associação mais dispensada, seguida da apresentação de sitagliptina associada à metformina que foi utilizada por apenas 7,6% dos pacientes. Para aqueles em que os níveis glicêmicos são de controle extremamente difícil, acrescentase pioglitazona à terapia com esses fármacos associados, fato constatado no total de 14,0% dos pacientes envolvidos no presente estudo (Figura 2). Interior do Piauí 4 4,3
Renda Familiar
Abaixo de um salário mínimo (R$ 880,00) Perfil dos pacientes diabéticos acompanhados pela assistência farmacêutica do Piauí, Brasil No presente estudo, o sexo feminino apresentou uma maior prevalência no DM2 (Tabela 1), fato que pode estar associado à maior preocupação das mulheres quanto ao autocuidado e à procura por serviços de saúde, apesar da doença ser, segundo a literatura, mais prevalente em homens. Para Galdas et al., (2015) , os homens, como grupo, são frequentemente sub-representados em muitos programas de atenção à saúde e acredita-se que no quesito autocuidado sejam mais negligentes do que as mulheres 9 . A participação de familiares pode ser um fator benéfico no manejo da doença. É importante repassar não somente ao paciente, mas também para os componentes do seu grupo familiar, as informações básicas sobre o tratamento do DM2. Dessa forma, é possível criar um ambiente que reforça a adesão através de atitudes simples como lembrar de uma consulta médica, o horário da administração da medicação, preparo de refeições saudáveis e incentivar a prática de exercícios físicos, por exemplo. Mayberry (2014) Este achado indica a necessidade de orientações sobre o controle do peso, uma vez que a obesidade é uma das comorbidades consideradas como fatores de risco quando associadas ao diabetes, assim como hipertensão e dislipidemias 16, 17 . Indivíduos que possuem concomitantemente DM2 e HAS, por exemplo, apresentam um maior risco para desenvolvimento de doença renal, doença cardíaca coronariana, acidente vascular encefálico e insuficiência cardíaca. Quando associadas à dislipidemia há aumento tanto da morbidade como da mortalidade nesses pacientes 18 . Por conta disso, medidas de prevenção do DM2 devem ser adotadas para reduzir ou evitar as referidas complicações, tais como, ações de educação em saúde e adoção de estilo de vida saudável, a fim de obter um controle glicêmico satisfatório 2 e de evitar a cultura de que apenas utilizando o medicamento será possível atingir o controle da doença (Tabela 2).
A dislipidemia, por sua vez, é uma alteração do metabolismo de lipoproteínas circulantes no sangue que nos portadores de DM2 é causada devido à resistência à insulina e à obesidade, podendo ser caracterizada pelo aumento na produção de glicose, hipertrigliceridemia e VLDL, associando-se a redução na HDL e elevação na LDL. Observou-se maior prevalência de dislipidemias no sexo feminino (Tabela 3), fato possivelmente associado à instalação da menopausa, pois com a redução dos níveis de estrogênio, ocorrem naturalmente mudanças no perfil lipídico como queda do colesterol HDL e aumento progressivo do colesterol LDL, do colesterol total e dos triglicerídeos 19, 20 . Além do descrito, indivíduos hipertensos frequentemente apresentam altos níveis de perfil lipídico, conforme destacado na Tabela 4. A associação destas condições apresenta forte influência da hipercolesterolemia que, por sua vez, contribui para a progressão da HAS 21 . Com relação aos níveis glicêmicos, os resultados encontrados foram em sua maioria satisfatórios quanto aos valores de glicemia de jejum (57%) e glicemia pós-prandial (75,3%) conforme estabelecido pela Sociedade Brasileira de Diabetes (2016). Porém, no que tange aos níveis de hemoglobina glicada (HbA1c), observou-se que 52,7% (Figura 1) não apresentavam controle glicêmico ideal, contrapondo o relato dos pacientes quanto a realização de atividade física e restrição alimentar elencados na tabela 2.
Tais resultados refletem que apesar da efetividade dos medicamentos dispensados, é latente a necessidade de atenção no atendimento aos pacientes diabéticos quanto ao repasse de informações relativas à fisiopatologia da doença e à necessidade da realização constante de atividades físicas e dieta, conforme citado anteriormente.
Quanto aos medicamentos dispensados, a presente pesquisa ressalta a possibilidade de ajuste do elenco medicamentoso da DUAF, o que resultaria em maior economia de gastos públicos pois, evitaria a compra de grandes quantidades de medicamentos que são pouco utilizados e que por consequência podem vir a ultrapassar o prazo de validade gerando prejuízos e resíduos de saúde, como ocorre, por exemplo com a associação de sitagliptina 50 mg com metformina 500 mg, dispensada a apenas 1,1% dos participantes (Figura 2).
Além disso, segundo a literatura, existem alternativas terapêuticas à vildagliptina, eficazes e de custo mais baixo disponíveis, dado relevante uma vez que este foi o princípio ativo mais recorrente na pesquisa (Figura 2). Kim et al., (2017), em estudo randomizado com 34 pacientes em monoterapia com metformina e com níveis glicêmicos não-controlados, observou que tanto a vildagliptina quanto a glimepirida quando associadas à terapia com metformina reduzem de forma semelhante a glicemia, o que poderia representar uma primeira linha de conduta terapêutica a ser adotada na dispensação de hipoglicemiantes orais junto à assistência farmacêutica piauiense.
No entanto, a vildagliptina se sobressai à glimepirida por não proporcionar ganho de peso e promover menor incidência de hipoglicemia 22 . Outro estudo recente desenvolvido por realizou análise de custo-efetividade da terapia com metformina combinada com vildagliptina ou glimepirida em 10 mil pacientes portadores de DM2 com níveis glicêmicos não-controlados. Observou-se que a adição de vildagliptina à terapia elevou de forma mais acentuada os custos do tratamento em comparação à adição de glimepirida. Entretanto, esse aumento foi minimizado pela diminuição dos custos das comorbidades associadas e eventos adversos, além do aumento dos anos de vida assim como da qualidade de vida dos pacientes usuários da terapia com vildagliptina, fato que ratifica a importância deste princípio ativo nas políticas de promoção, proteção e recuperação da saúde dos diabéticos mas que vem a salientar a necessidade da adoção de critérios na aquisição, solicitação e dispensação de medicamentos à base de vildagliptina 23 . Sugere-se como futuro critério de inclusão de um protocolo clínico estadual de dispensação de vildagliptina, a realização prévia constatada de tratamento associado de glimepirida com metformina pelos pacientes com DM2, a fim de, racionalizar a aquisição e o uso do medicamento.
Dessa forma, é indispensável a atuação do profissional farmacêutico junto a esses pacientes proporcionando acompanhamento farmacoterapêutico e avaliação técnica dos tratamentos solicitados, assim como na atuação específica da gestão dos recursos envolvidos na Assistência Farmacêutica o que contribui para uma melhor qualidade de vida dos pacientes e melhor aplicação dos recursos do Sistema Único de Saúde (SUS).
CONCLUSÃO
Os pacientes com DM2 assistidos pela DUAF são preponderantemente indivíduos sobrepeso, do sexo feminino, acima dos 60 anos de idade, residentes na capital Teresina com ensino médio completo e renda familiar mensal de um salário mínimo.
A pesquisa revelou que apesar de grande parte dos participantes terem relatado ser praticante de atividade física regular (53,8%) e de restrições alimentares (87,1%), apenas 26,9% do total de pacientes apresentavam IMC normal. Além disso, 52,7% possuíam controle glicêmico insatisfatório a partir dos valores de HbA1c, principal marcador laboratorial de avaliação do paciente diabético. O fármaco mais utilizado foi a vildagliptina 50mg, seguida pela sua apresentação farmacológica associada à metformina. Constata-se a notória necessidade de constante acompanhamento farmacêutico do grupo de pacientes alvo do presente estudo. Além disso, recomenda-se a associação de novos exames laboratoriais para a avaliação dos riscos e benefícios da terapia hipoglicemiante oral, como por exemplo, lipidograma, dosagem de transaminases hepáticas e provas de função renal, sobretudo se considerado que a maioria significativa dos pacientes apresenta comorbidades, Da mesma forma, sugere-se o ajuste no rol de medicamentos padronizados pela DUAF, principalmente no que tange ao ativo vildagliptina, assim como a instituição de Comissão Multidisciplinar de Farmácia e Terapêutica para a elaboração de PCDT, a fim de incentivar o uso racional dos medicamentos e a otimização dos recursos públicos da saúde destinados ao paciente diabético do Piauí.
